How to better select patients with advanced gastric cancer for immunotherapy.
作者信息
Zaanan Aziz, Taieb Julien
机构信息
Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France.
Paris Descartes University, Sorbonne Paris Cité, Paris, France.
出版信息
Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019.
Abstract
摘要
相似文献
1
How to better select patients with advanced gastric cancer for immunotherapy.如何更好地为晚期胃癌患者选择免疫治疗方案。
Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019.
2
Immunotherapy in advanced gastric cancer, is it the future?免疫治疗在晚期胃癌中的应用，是否代表未来？
Crit Rev Oncol Hematol. 2019 Jan;133:25-32. doi: 10.1016/j.critrevonc.2018.10.007. Epub 2018 Nov 2.
3
[Progression of immunotherapy in gastric cancer].[胃癌免疫治疗的进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Feb;19(2):225-32.
4
Unresectable advanced gastric cancer effectively treated by combined chemo-immunotherapy: a report of two cases.联合化疗免疫疗法有效治疗不可切除的晚期胃癌：两例报告
Kurume Med J. 2000;47(2):177-82. doi: 10.2739/kurumemedj.47.177.
5
Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer.6589例胃癌患者的手术结果以及免疫化疗手术作为晚期胃癌的最佳治疗方法。
Ann Surg. 1992 Sep;216(3):269-78; discussion 278-9. doi: 10.1097/00000658-199209000-00006.
6
The pilot experience of immunotherapy-combined photodynamic therapy for advanced gastric cancer in elderly patients.老年晚期胃癌免疫治疗联合光动力治疗的初步经验
Int J Gastrointest Cancer. 2002;32(2-3):139-42. doi: 10.1385/IJGC:32:2-3:139.
7
Effect of splenectomy and immunotherapy on advanced gastric cancer associated with total gastrectomy.脾切除术和免疫疗法对全胃切除术后进展期胃癌的影响。
Jpn J Surg. 1983 Jan;13(1):20-4. doi: 10.1007/BF02469685.
8
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.免疫疗法在晚期胃癌和食管癌治疗中的应用
Anticancer Res. 2018 Oct;38(10):5569-5580. doi: 10.21873/anticanres.12891.
9
Pembrolizumab for the treatment of gastric cancer.帕博利珠单抗治疗胃癌。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1177-1187. doi: 10.1080/14737140.2018.1526084. Epub 2018 Oct 3.
10
Splenectomy combined with gastrectomy and immunotherapy for advanced gastric cancer.脾切除术联合胃切除术及免疫疗法治疗晚期胃癌。
Acta Med Okayama. 1983 Jun;37(3):251-8. doi: 10.18926/AMO/32439.
引用本文的文献
1
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry.胃肠道癌症中的微卫星状态检测：在错配修复蛋白免疫组化结果为阴性/局灶性的情况下，聚合酶链反应/二代测序是必需的
Cancers (Basel). 2022 Apr 28;14(9):2204. doi: 10.3390/cancers14092204.
2
Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.在分子医学时代，传统组织病理学还有一席之地吗？劳伦分类、炎症浸润及胃癌诊断与预后的其他当前主题。
Histol Histopathol. 2021 Jun;36(6):587-613. doi: 10.14670/HH-18-309. Epub 2021 Feb 10.
3
Expression and role of nuclear receptor-interacting protein 1 (NRIP1) in stomach adenocarcinoma.核受体相互作用蛋白1（NRIP1）在胃腺癌中的表达及作用
Ann Transl Med. 2020 Oct;8(20):1293. doi: 10.21037/atm-20-6197.
本文引用的文献
1
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.转移性结直肠癌中免疫检查点抑制剂原发性耐药与微卫星不稳定性或错配修复缺陷状态误诊的关联。
JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942.
2
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.avelumab 对比医师选择的化疗作为晚期胃癌或胃食管结合部癌三线治疗的 III 期随机试验：JAVELIN Gastric 300 的主要分析结果
Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
3
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.PD-1 抑制治疗转移性胃癌的临床反应的全面分子特征分析。
Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.
4
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
5
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
6
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
7
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
8
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.纳武利尤单抗治疗转移性DNA错配修复缺陷或微卫星高度不稳定结直肠癌患者（CheckMate 142）：一项开放标签、多中心、2期研究。
Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
9
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).转移性结直肠癌患者循环肿瘤 DNA 作为疗效标志物的早期评估（PLACOL 研究）。
Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.
10
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
Zotero 插件